Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02393625 · ClinicalTrials.gov registry record · Phase 1
Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer
A Phase 1 study of ALK-positive NSCLC, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 12
- Study locations
NCT02393625: Active Phase 1 study of ALK-positive NSCLC, sponsored by Novartis Pharmaceuticals.
NCT02393625 is a Phase 1 study of ALK-positive NSCLC that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02393625, a Phase 1 study of ALK-positive NSCLC, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
Conditions Studied
Interventions
- DRUG Nivolumab
- DRUG Ceritinib (LDK378)
Study Locations (12)
Other
- Novartis Investigative Site - Hong Kong
- Novartis Investigative Site - Singapore
- Novartis Investigative Site - Barcelona
Massachusetts
- Massachusetts General Hospital - Boston
- Massachusetts General Hospital Thoracic Oncolgoy - Boston
Arizona
- Mayo Clinic - Arizona - Scottsdale
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Victoria
- Novartis Investigative Site - Heidelberg
Vlaams Brabant
- Novartis Investigative Site - Leuven
Ontario
- Novartis Investigative Site - Toronto
MI
- Novartis Investigative Site - Milan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2015-05-27 |
| Est. Completion | 2027-04-09 |
| Phase | Phase 1 |
What the registry record for NCT02393625 still lists
NCT02393625 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with ALK-positive NSCLC appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.
NCT02393625 lists 12 locations in 9 states (Other, Massachusetts, Arizona).
Frequently Asked Questions
What is clinical trial NCT02393625 about?
NCT02393625 is a clinical study titled "Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer". This is an open label multi center trial to determine the safety and efficacy of ceritinib in combination with nivolumab in ALK-positive NSCLC patients
What is the current status of trial NCT02393625?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2015-05-27. Estimated completion is 2027-04-09.
What conditions does trial NCT02393625 study?
This clinical trial studies the following conditions: ALK-positive NSCLC.
What interventions are being tested in trial NCT02393625?
The interventions under investigation include: Nivolumab (DRUG), Ceritinib (LDK378) (DRUG).
Who is sponsoring clinical trial NCT02393625?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02393625 being conducted?
This trial has 12 study locations across Arizona, Massachusetts, Pennsylvania, Victoria, Vlaams Brabant. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02393625's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI